EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cystatin C as Biomarker for the Evaluation of Renal Outcome in AL Amyloidosis

Foteini Theodorakakou iD, Despina Fotiou, Filia Apostolakou, Ioannis Papassotiriou, Vasiliki Spiliopoulou, Ioannis Ntanasis-Stathopoulos iD, Panagiotis Malandrakis, Magdalini Migkou, Nikolaos Kanellias, Evangelos Eleutherakis-Papaiakovou, Erasmia Psimenou, Asimina Papanikolaou und 7 weitere

American Journal of Hematology · 2025

DOI: 10.1002/ajh.27716 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Hematology, 2025. Verfasst von Foteini Theodorakakou und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece. Hauptthemen laut MEDLINE: Cystatin C, Immunoglobulin Light-chain Amyloidosis, Amyloidosis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cystatin C (CysC) has emerged as a novel and potentially more reliable biomarker for the estimation of glomerular filtration in the general population in patients with various conditions. In AL amyloidosis, the current renal staging system and renal response criteria are based on proteinuria and creatinine‐based eGFR. We explored the prognostic role of CysC and of estimation of eGFR based on CysC‐based equations in a cohort of 195 patients with newly diagnosed AL amyloidosis with renal involvement. Baseline CysC level was strongly and independently associated with progression to dialysis, and CysC levels ≥ 1.9 mg/L can be used in combination with the current renal staging system to identify patients with different risk of progression to dialysis among renal stages 2 and 3. eGFR based on CysC performed at least similarly to eGFR based on creatinine alone (by CKD‐EPI race free formula) and the cutoff of 30 mL/min/1.73 m 2 could better predict progression to dialysis at 2 years. At 6 months landmark, an increase in CysC by ≥ 1 mg/L was associated with higher risk of progression to dialysis (HR: 19.8, 95% CI 6.5–60.5, p < 0.001); a reduction of CysC based eGFR ≥ 30% was also associated with poor renal outcome, with a prognostic performance similar to current renal progression criteria. In conclusion, CysC provides prognostic information regarding the renal outcomes in patients with AL amyloidosis independently of the established biomarkers, but requires further validation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystatin CImmunoglobulin Light-chain AmyloidosisAmyloidosisHumansMaleBiomarkersFemaleMiddle AgedGlomerular Filtration RateAgedPrognosisDisease ProgressionRenal DialysisCreatinine

Stichwörter der Autor:innen

cystatin Cdialysisglomerular filtration ratekidneylight chain amyloidosis

Substanzen

Cystatin CBiomarkersCST3 protein, humanCreatinine

Autor:innen und Institutionen

  • Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.
  • Department of Clinical Biochemistry, "Aghia Sophia" Children's Hospital, Athens, Greece.
  • First Department of Pediatrics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
  • Department of Haemopathology, Evangelismos Hospital, Athens, Greece.
  • First Department of Pathology, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
  • Clinic of Nephrology and Renal Transplantation, National and Kapodistrian University of Athens, School of Medicine, Laikon Hospital, Athens, Greece.

ORCID-Profile: Foteini Theodorakakou, Ioannis Ntanasis-Stathopoulos, Maria Gavriatopoulou, Meletios-Athanasios Dimopoulos, Efstathios Kastritis

Zitieren

APA

Theodorakakou, F., Fotiou, D., Apostolakou, F., Papassotiriou, I., Spiliopoulou, V., Ntanasis-Stathopoulos, I., Malandrakis, P., Migkou, M., Kanellias, N., Eleutherakis-Papaiakovou, E., Psimenou, E., Papanikolaou, A., Gakiopoulou, C., Marinaki, S., Giannouli, S., Gavriatopoulou, M., Terpos, E., Dimopoulos, M. A., & Kastritis, E. (2025). Cystatin C as Biomarker for the Evaluation of Renal Outcome in AL Amyloidosis. American Journal of Hematology. https://doi.org/10.1002/ajh.27716

Vancouver

Theodorakakou F, Fotiou D, Apostolakou F, Papassotiriou I, Spiliopoulou V, Ntanasis-Stathopoulos I, et al. Cystatin C as Biomarker for the Evaluation of Renal Outcome in AL Amyloidosis. American Journal of Hematology. 2025. doi:10.1002/ajh.27716

BibTeX
@article{Theodorakakou2025,
  author = {Theodorakakou, Foteini and Fotiou, Despina and Apostolakou, Filia and Papassotiriou, Ioannis and Spiliopoulou, Vasiliki and Ntanasis-Stathopoulos, Ioannis and Malandrakis, Panagiotis and Migkou, Magdalini and Kanellias, Nikolaos and Eleutherakis-Papaiakovou, Evangelos and Psimenou, Erasmia and Papanikolaou, Asimina and Gakiopoulou, Charikleia and Marinaki, Smaragdi and Giannouli, Stavroula and Gavriatopoulou, Maria and Terpos, Evangelos and Dimopoulos, Meletios-Athanasios and Kastritis, Efstathios},
  title = {Cystatin C as Biomarker for the Evaluation of Renal Outcome in AL Amyloidosis},
  journal = {American Journal of Hematology},
  year = {2025},
  doi = {10.1002/ajh.27716}
}
Kostenlos starten →